Urol. praxi. 2025;26(3):128-136 | DOI: 10.36290/uro.2025.069

Modern approaches to the management of benign prostatic hyperplasia in elderly men

doc. MUDr. Jozef Marenčák, PhD.
Bratislava

Benign prostatic hyperplasia (BPH) is a common urological condition that has a significant impact on patients' quality of life and an economic burden on healthcare systems worldwide, and is likely to become increasingly common in the aging population. While transurethral resection of the prostate and medical management still play an important role in the treatment of BPH, a number of alternatives are now available, including laser enucleation and minimally invasive techniques. The choice of the most appropriate therapeutic modality will depend on the patient's individual preferences, current health status, resource availability, cost, anatomical factors, and treatment goals.

Keywords: benign prostatic hyperplasia, older man, current treatment options.

Accepted: September 29, 2025; Published: October 17, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marenčák J. Modern approaches to the management of benign prostatic hyperplasia in elderly men. Urol. praxi. 2025;26(3):128-136. doi: 10.36290/uro.2025.069.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 17.10.2026

    References

    1. Codelia-Anjum A, Berjaoui M, Khondker A, et al. Procedural intervention for benign prostatic hyperplasia in men ≥ age 70 years - a review of published literature. Clin Interv Aging. 2023;18:1705-1717. Go to original source... Go to PubMed...
    2. Griebling T. Aging and geriatric urology. In: Partin A, Dmochowski R, Kavoussi L, et al. Campbell - Walsh Urology, 12th edition, Saunders Elsevier 2021; ISBN 978-0-323-54642-3: 2905-2907.
    3. Van Huele A, Samarinas M, Bower W, et al. Optimizing care for LUTS in older patients: diagnostics, challenges of frailty and patient priorities - NOPIA meeting (ICI-RS 2024). Continence. 2025;13:101737. Go to original source...
    4. Rockwood K, Howlett S. Fifteen years of progress in understanding frailty and health in aging. BMC Med. 2018;16(1): https://doi.org/10.1186/s12916-018-1223-3. Go to original source... Go to PubMed...
    5. Zillioux J, Ladwa A, Holum P, et al. Minimally invasive therapies for older patients with urgency urinary incontinence: current evidence and recommendations. Continence. 2025;13:101733. Go to original source...
    6. Cornu J, Gacci M, Hashim H, et al. EAU guidelines on non-neurogenic male lower urinary tract symtoms (LUTS). https://uroweb.org/guidelines, prístup od 3. 2. 2025.
    7. Hughes T, Harper P, Somani B. Treatment algorithm for management of benign prostatic obstruction: an overview of current techniques. Life. 2023;13(10):2077. https://doi.org/10.3390/life13102077. Go to original source... Go to PubMed...
    8. Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older person: results of a systematic literature review and internaqtional consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745-755. Go to original source... Go to PubMed...
    9. Bortnick E, Brown C, Simma-Chiang V, et al. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. 2020;12:1-11. Go to original source... Go to PubMed...
    10. Halawani A, Paterson R, Zhong T, et al. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate Int. 2024;12(2):57-64. Go to original source... Go to PubMed...
    11. Marenčák J. Čo je nové vo farmakoterapii benígnej hyperplázie prostaty. Klin Farmakol Farm. 2023;37(1):10-18. Go to original source...
    12. Oelke M, Wagg A, Takita Y, et al. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men > 75 years: integrated analysis of pooled data from multi­national, randomized, placebo-controled clinical studies. BJU Int. 2017;119(5):793-803. Go to original source... Go to PubMed...
    13. Sinha S, Cameron A, Tse V, et al. Storage-dominant lower urinary tract symptoms in the older male: practical approach, guidelines recommendations and limitations of evidence. Continence. 2024;11:101320. Go to original source...
    14. Lerner L, McVary K, Barry M, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline Part I-Initial work-up and medical management. J Urol. 2021;206(4):806-817. Go to original source... Go to PubMed...
    15. Franco J, Trivisonno L, Sgarbossa N, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023;6(6):CD001423. Go to original source... Go to PubMed...
    16. Franco J, Tesolin P, Jung J. Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures. Prostate Int. 2023;11(1):1-7. Go to original source... Go to PubMed...
    17. Lotterstätter M, Seklehner S, Wimpissinger F, et al. Transurethral resection of the prostate in 85+ patients: a retrospective, multicenter study. World J urol. 2022;40(12):3015-3020. Go to original source... Go to PubMed...
    18. Hartung F, Kowalewski K, von Hardenberg J, et al. Holmium versus thulium laser enucleation of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus. 2022;8(2):545-554. Go to original source... Go to PubMed...
    19. Nottingham C, Large T, Agarwal D, et al. Comparison of newly optimized Moses technology versus standard holmium:YAG for endoscopic laser enucleation of the prostate. J Endourol. 2021;35(9):1393-1399. Go to original source... Go to PubMed...
    20. Bouhadana D, Bguyen D, Zhang X, et al. Safety and efficacy of TURP vs laser prostatectomy for the treatment of benign prostatic hyperplasia in multi-morbid and elderly individuals aged ≥ 75. World J Urol. 2021;39(12):4405-4412. Go to original source... Go to PubMed...
    21. Yim A, Alberto M, Yan X, et al. Comparing Greenlight PVP and HoLEP beyond 5 years: a systematic review of long-term functional outcomes and reoperative rates. BJU Compass. 2025;6(2):e483. Go to original source... Go to PubMed...
    22. Chen D, Qu I, Webb L, et al. Aquablation in men with benign prostatic hyperplasia: a systematic review and meta-analysis. Curr Urol. 2023;17(1):68-76. Go to original source... Go to PubMed...
    23. Gangwish D, Jabeer M, Kennedy A, et al. Aquablation compared with simple prostatectomy for prostate volumes > 80 grams. J Endourol, 2025 Feb 21; doi: 10.1089/end.2024.0583. Online ahead of print. Go to original source... Go to PubMed...
    24. Roehrborn C, Barkin J, Gange S, et al. Five year results of the prospective randomized controlled prostatis urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802-8814. Go to original source...
    25. Shah B, Tayon K, Madiraju S, et al. Prostatic urethral lift: does size matter? J Endourol. 2018;32(7):635-638. Go to original source... Go to PubMed...
    26. Lehner K, Popat S, Utech K, et al. Outcomes of prostatic urethral lift in a medically complex population at a veterans affairs hospital. BJU Compass. 2022;3(3):214-219. Go to original source... Go to PubMed...
    27. Knight L, Dale M, Cleves A, et al. Urolift for treating lower urinary tract symptoms of benign prostatic hyperplasia: a NICE medical technology guidance update. Appl Health Econ Health Policy. 2022;20(5):669-680. Go to original source... Go to PubMed...
    28. Babar M, Loloi J, Tang K, et al. Emerging outcomes of water wapor thermal therapy (Rezűm) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. Low Urin Tract Symptoms. 2022;14(3):140-154. Go to original source... Go to PubMed...
    29. Bassily D, Wong V, Phillips J, et al. Rezűm for retention - retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia. Prostate. 2021;81(14):1049-1054. Go to original source... Go to PubMed...
    30. Bhatia S, Sinha V, Kava B, et al. Efficacy of prostatic artery embolization for catheter-dependent patients with large prostate sizes and high comorbidity scores. J Vasc Interv Radiol. 2018;29(1):78-84. Go to original source... Go to PubMed...
    31. Bagla S, Singh I,Sajan A, et al. Combination prostatic artery embolization prior to water-jet ablation (Aquablation) for benign prostatic hypertrophy: a propensity score analysis. J Clin Med, 2024;13(22):6930. doi: 10.3390/jcm13226930. Go to original source... Go to PubMed...
    32. Chughtai B, Elterman D, Shore N, et al. The ITind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial. Urology. 2021;153:270-276. Go to original source... Go to PubMed...
    33. Kaplan S, Moss J, Freedman S. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE study). Prostate Cancer Prostatic Dis. 2024;27(3):531-536. Go to original source... Go to PubMed...
    34. Pichardo M, Rijo E, Espino G, et al. Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study. World J Urol. 2023;41(8):2209-2215. Go to original source... Go to PubMed...
    35. Fourmarier M, Baboudjian M, Robert G, et al. Is there a best timing for benign prostatic hyperplasia surgery? Fr J Urol. 2024;34(2):102574. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.